PLoS ONE (Jan 2019)

Pancreatic 18F-FDG uptake is increased in type 2 diabetes patients compared to non-diabetic controls.

  • Guido J Bakker,
  • Manon C Vanbellinghen,
  • Torsten P Scheithauer,
  • C Bruce Verchere,
  • Erik S Stroes,
  • Nyanza K L M Timmers,
  • Hilde Herrema,
  • Max Nieuwdorp,
  • Hein J Verberne,
  • Daniël H van Raalte

DOI
https://doi.org/10.1371/journal.pone.0213202
Journal volume & issue
Vol. 14, no. 3
p. e0213202

Abstract

Read online

IntroductionIncreasing evidence indicates that the development of type 2 diabetes is driven by chronic low grade beta-cell inflammation. However, it is unclear whether pancreatic inflammation can be noninvasively visualized in type 2 diabetes patients. We aimed to assess pancreatic 18F-FDG uptake in type 2 diabetes patients and controls using 18F-fluorodeoxylglucose positron emission tomography/computed tomography (18F-FDG PET/CT).Material and methodsIn this retrospective cross-sectional study, we enrolled 20 type 2 diabetes patients and 65 controls who had undergone a diagnostic 18F-FDG PET/CT scan and obtained standardized uptake values (SUVs) of pancreas and muscle. Pancreatic SUV was adjusted for background uptake in muscle and for fasting blood glucose concentrations.ResultsThe maximum pancreatic SUVs adjusted for background muscle uptake (SUVmax.m) and fasting blood glucose concentration (SUVglucose) were significantly higher in diabetes patients compared to controls (median 2.86 [IQR 2.24-4.36] compared to 2.15 [IQR 1.51-2.83], p = 0.006 and median 2.76 [IQR 1.18-4.34] compared to 1.91 [IQR 1.27-2.55], pConclusionPancreatic 18F-FDG uptake adjusted for background muscle uptake and fasting blood glucose concentration was significantly increased in type 2 diabetes patients.